Results from a Phase 1 clinical trial evaluating the safety and immunogenicity of Emergent BioSolutions’ (NYSE:EBS) Zika vaccine, VLA1601, showed a favorable safety profile for all doses and schedules tested and encouraging immunogenic activity.
{iframe}https://seekingalpha.com/news/3411069-emergent-bios-zika-vaccine-shows-positive-action-early-stage-study#email_link{/iframe}